What Is Brain-Derived Neurotrophic Factor

Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family that supports the growth, differentiation, and survival of neurons in the central and peripheral nervous systems. It is most concentrated in the hippocampus, cortex, and basal forebrain, regions essential for learning, memory, and higher cognition. BDNF acts by binding to the TrkB receptor on neuronal surfaces, triggering intracellular signaling cascades that strengthen synapses and promote neuronal resilience.

The brain's ability to form new connections and maintain existing ones does not remain constant across the lifespan. BDNF is one of the primary molecular regulators of this capacity, known as synaptic plasticity. When BDNF signaling is robust, neurons communicate more efficiently, new memories consolidate more readily, and damaged circuits have a better chance of recovery. When BDNF signaling weakens, the brain becomes more vulnerable to the cumulative effects of aging, metabolic stress, and neuroinflammation.

From a longevity perspective, BDNF sits at the intersection of several aging processes. Its levels correlate with hippocampal volume, which shrinks measurably with each decade past midlife. Reduced BDNF signaling has been observed in the early stages of neurodegenerative conditions including Alzheimer's disease. Because BDNF production is strongly influenced by modifiable behaviors such as physical activity, sleep, and dietary patterns, it represents one of the more actionable molecular targets for maintaining cognitive function across decades.

BDNF is synthesized as a precursor protein called pro-BDNF, which is cleaved into its mature form either inside the neuron or in the extracellular space. The mature protein binds to the tropomyosin receptor kinase B (TrkB) receptor, activating three major downstream pathways: the MAPK/ERK pathway (which promotes cell survival and differentiation), the PI3K/Akt pathway (which inhibits apoptosis), and the PLCγ pathway (which modulates synaptic plasticity and calcium signaling). Interestingly, pro-BDNF binds preferentially to a different receptor, p75NTR, and can promote synaptic weakening or even cell death, meaning the ratio of pro-BDNF to mature BDNF matters for the net biological effect.

The most well-characterized function of mature BDNF involves long-term potentiation (LTP) in the hippocampus. LTP is the process by which repeated activation of a synapse strengthens the connection between two neurons, forming the cellular basis of memory encoding. BDNF facilitates LTP by increasing the density of dendritic spines, enhancing neurotransmitter release, and upregulating the expression of proteins required for synaptic maintenance. Without sufficient BDNF, LTP is impaired and memory consolidation suffers.

BDNF production is tightly regulated by neural activity, hormonal signals, and metabolic status. Physical exercise, particularly sustained aerobic effort, increases BDNF expression through mechanisms involving irisin (a myokine released by contracting muscle), lactate signaling across the blood-brain barrier, and activation of the transcription factor CREB. Conversely, chronic elevation of cortisol, systemic inflammation (particularly elevated IL-6 and TNF-alpha), and hyperglycemia each suppress BDNF transcription. This bidirectional regulation means that the same lifestyle factors influencing cardiovascular and metabolic health also shape the brain's neurotrophic environment.

The scientific literature on BDNF is extensive, spanning thousands of publications across animal models and human studies. The relationship between aerobic exercise and BDNF elevation is supported by multiple meta-analyses of randomized controlled trials, with consistent findings that acute bouts of aerobic activity produce transient spikes in serum BDNF and that chronic training raises baseline levels. The association between low serum BDNF and neurodegenerative conditions, particularly Alzheimer's disease and major depressive disorder, is supported by large epidemiological datasets and post-mortem brain tissue analyses.

Important gaps remain. Serum BDNF measurements do not directly reflect brain tissue concentrations, and the contribution of platelet-stored BDNF to blood measurements introduces variability. Whether pharmacologically or supplementally raising BDNF in humans translates to measurable cognitive benefits has not been established through large, long-duration randomized trials. Most supplement-related BDNF data (lion's mane, curcumin, omega-3s) comes from animal models or small, short-duration human studies without cognitive endpoints as primary outcomes. The genetics of BDNF are also relevant: the Val66Met polymorphism (rs6265), carried by roughly 30% of the population depending on ancestry, impairs activity-dependent BDNF secretion and may modify the cognitive benefits of exercise, though this finding requires further replication.

BDNF itself is not an exogenous substance that people take, so traditional safety concerns do not apply in the same way as for a drug or supplement. However, several nuances warrant consideration. Excessively high BDNF signaling has been implicated in certain pathological states, including epilepsy and some forms of chronic pain, where overactive TrkB signaling contributes to neural hyperexcitability. The Val66Met genetic variant may influence individual responsiveness to BDNF-boosting interventions, and interpreting serum BDNF lab results without understanding their limitations (platelet contamination, diurnal variation, assay differences) can lead to misguided conclusions. Anyone considering pharmacological approaches to modulate BDNF should weigh the incomplete evidence base carefully.